Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.

Bénichou B, Goyal S, Sung C, Norfleet AM, O'Brien F.

Mol Genet Metab. 2009 Jan;96(1):4-12. doi: 10.1016/j.ymgme.2008.10.004. Epub 2008 Nov 20.

PMID:
19022694
2.

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP; International Fabry Disease Study Group.

Am J Hum Genet. 2004 Jul;75(1):65-74. Epub 2004 May 20.

3.

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.

Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, Germain DP.

J Pediatr. 2008 Apr;152(4):563-70, 570.e1. doi: 10.1016/j.jpeds.2007.09.007. Epub 2007 Dec 3.

PMID:
18346516
4.

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM.

Kidney Int. 2004 Oct;66(4):1589-95.

5.

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.

Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, Warnock DG.

Mol Genet Metab. 2012 Mar;105(3):443-9. doi: 10.1016/j.ymgme.2011.12.006. Epub 2011 Dec 14.

PMID:
22227322
6.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.

7.

Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.

Tanaka A, Takeda T, Hoshina T, Fukai K, Yamano T.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S249-52. doi: 10.1007/s10545-010-9136-0. Epub 2010 Jun 22.

PMID:
20567910
8.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
9.

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, Ten Berge IJ, Groener JE, Aerts JM, Wanner C, Hollak CE.

Mol Genet Metab. 2008 Jul;94(3):319-25. doi: 10.1016/j.ymgme.2008.03.003. Epub 2008 Apr 18.

PMID:
18424138
10.

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.

Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska A.

Genet Med. 2009 Apr;11(4):256-64. doi: 10.1097/GIM.0b013e3181981d82.

PMID:
19265719
11.

Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Deegan PB.

J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25. Review.

PMID:
22037707
12.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
13.

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.

Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y.

Mol Genet Metab. 2007 Nov;92(3):271-3. Epub 2007 Aug 8.

PMID:
17689998
14.

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

Warnock DG, Bichet DG, Holida M, Goker-Alpan O, Nicholls K, Thomas M, Eyskens F, Shankar S, Adera M, Sitaraman S, Khanna R, Flanagan JJ, Wustman BA, Barth J, Barlow C, Valenzano KJ, Lockhart DJ, Boudes P, Johnson FK.

PLoS One. 2015 Aug 7;10(8):e0134341. doi: 10.1371/journal.pone.0134341. eCollection 2015.

15.

Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.

Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, Cagnoli L.

Kidney Int. 2004 Apr;65(4):1381-5.

16.

Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.

Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, Sakai N, Kitagawa T, Suzuki Y, Mochizuki S, Kawakami M, Hosoya T, Owada M, Sakuraba H, Saito H.

J Inherit Metab Dis. 2005;28(4):575-83.

PMID:
15902561
17.

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R.

J Clin Pharmacol. 2007 Oct;47(10):1222-30. Epub 2007 Aug 13.

PMID:
17698592
18.

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.

Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP.

Genet Med. 2008 May;10(5):353-8. doi: 10.1097/GIM.0b013e318170f868.

PMID:
18496035
19.

Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N.

Nephrol Dial Transplant. 2007 Jul;22(7):1920-5. Epub 2007 Mar 29.

PMID:
17395657
20.

Supplemental Content

Support Center